Efficacy and Safety of Leflunomide for Refractory COVID-19: A Pilot Study

Efficacy and Safety of Leflunomide for Refractory COVID-19: A Pilot Study

Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may persist in patients with coronavirus disease 2019 (COVID-19) despite receiving standard care.Methods: In this pilot study of hospitalized adult patients (≥18 years of age), with radiologically confirmed pneumonia who we...

Full description

Bibliographic Details
Main Authors: Qiang Wang, Haipeng Guo, Yu Li, Xiangdong Jian, Xinguo Hou, Ning Zhong, Jianchun Fei, Dezhen Su, Zhouyan Bian, Yi Zhang, Yingying Hu, Yan Sun, Xueyuan Yu, Yuan Li, Bei Jiang, Yan Li, Fengping Qin, Yingying Wu, Yanxia Gao, Zhao Hu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Pharmacology
Subjects:
COVID-19
leflunomide
refractory
pilot study
safety
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.581833/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.581833/full

Similar Items